A class of highly selective inhibitors bind to an active state of PI3Kγ

被引:0
|
作者
Gangadhara Gangadhara
Göran Dahl
Thomas Bohnacker
Rebecca Rae
Jenny Gunnarsson
Stefan Blaho
Linda Öster
Helena Lindmark
Kostas Karabelas
Nils Pemberton
Christian Tyrchan
Mickael Mogemark
Matthias P. Wymann
Roger L. Williams
Matthew W. D. Perry
Tineke Papavoine
Jens Petersen
机构
[1] AstraZeneca,Discovery Sciences, IMED Biotech Unit
[2] University of Basel,Department of Biomedicine
[3] IMED Biotech Unit,Respiratory, Inflammation & Autoimmunity
[4] AstraZeneca,Drug Safety and Metabolism
[5] IMED Biotech Unit,undefined
[6] AstraZeneca,undefined
[7] MRC Laboratory of Molecular Biology,undefined
来源
Nature Chemical Biology | 2019年 / 15卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
We have discovered a class of PI3Kγ inhibitors exhibiting over 1,000-fold selectivity over PI3Kα and PI3Kβ. On the basis of X-ray crystallography, hydrogen-deuterium exchange–mass spectrometry and surface plasmon resonance experiments we propose that the cyclopropylethyl moiety displaces the DFG motif of the enzyme away from the adenosine tri-phosphate binding site, inducing a large conformational change in both the kinase- and helical domains of PI3Kγ. Site directed mutagenesis explained how the conformational changes occur. Our results suggest that these cyclopropylethyl substituted compounds selectively inhibit the active state of PI3Kγ, which is unique to these compounds and to the PI3Kγ isoform, explaining their excellent potency and unmatched isoform selectivity that were confirmed in cellular systems. This is the first example of a Class I PI3K inhibitor achieving its selectivity by affecting the DFG motif in a manner that bears similarity to DFG in/out for type II protein kinase inhibitors.
引用
收藏
页码:348 / 357
页数:9
相关论文
共 50 条
  • [21] Development of PI3Kγ selective inhibitors: the strategies and application
    Dong-yan Gu
    Meng-meng Zhang
    Jia Li
    Yu-bo Zhou
    Rong Sheng
    [J]. Acta Pharmacologica Sinica, 2024, 45 : 238 - 247
  • [22] Development of Scalable Syntheses of Selective PI3K inhibitors
    Huang, Qinhua
    Richardson, Paul F.
    Sach, Neal W.
    Zhu, Jinjiang
    Liu, Kevin K-C.
    Smith, Graham L.
    Bowles, Daniel M.
    [J]. ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2011, 15 (03) : 556 - 564
  • [23] 4-Methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors
    Liu, Kevin K-C.
    Bagrodia, Shubha
    Bailey, Simon
    Cheng, Hengmiao
    Chen, Hui
    Gao, Lisa
    Greasley, Samantha
    Hoffman, Jacqui E.
    Hu, Qiyue
    Johnson, Ted O.
    Knighton, Dan
    Liu, Zhengyu
    Marx, Matthew A.
    Nambu, Mitchell D.
    Ninkovic, Sacha
    Pascual, Bernadette
    Rafidi, Kristina
    Rodgers, Caroline M-L.
    Smith, Graham L.
    Sun, Shaoxian
    Wang, Haitao
    Yang, Anle
    Yuan, Jing
    Zou, Aihua
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (20) : 6096 - 6099
  • [24] Biomarker evaluation In phase I clinical trials of selective PI3K and PI3K/mTOR inhibitors
    Spoerke, Jill
    O'Brien, Carol
    Wu, Jenny
    Desai, Rupal
    Patel, Rajesh
    Raja, Rajiv
    Koeppen, Hartmut
    Amler, Lukas
    Hampton, Garret
    Yan, Yibing
    Lackner, Mark R.
    [J]. CANCER RESEARCH, 2012, 72
  • [25] Biomarker evaluation in phase I clinical trials of selective PI3K and PI3k/mTOR inhibitors
    Spoerke, Jill
    Desai, Rupal
    Patel, Rajesh
    Fredrickson, Jill
    Wang, Yulei
    Levy, Gallia
    Gendreau, Steve
    Lauchle, Jennifer
    Derynck, Mika
    Raja, Rajiv
    Koeppen, Hartmut
    Hampton, Garret
    Yan, Yibing
    Lackner, Mark R.
    [J]. CANCER RESEARCH, 2013, 73 (08)
  • [26] Discovery of Highly Isoform Selective Orally Bioavailable Phosphoinositide 3-Kinase (PI3K)-γ Inhibitors
    Pemberton, Nils
    Mogemark, Mickael
    Arlbrandt, Susanne
    Bold, Peter
    Cox, Rhona J.
    Gardelli, Cristina
    Holden, Neil S.
    Karabelas, Kostas
    Karlsson, Johan
    Lever, Sarah
    Li, Xueshan
    Lindrnark, Helena
    Norberg, Monica
    Perry, Matthew W. D.
    Petersen, Jens
    Blomqvist, Sandra Rodrigo
    Thomas, Matthew
    Tyrchan, Christian
    Eriksson, Annika Westin
    Zlatoidsky, Pavol
    Osterg, Linda
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (12) : 5435 - 5441
  • [27] Resveratrol and resveratrol derivatives as class IA PI3K inhibitors
    Petty, Cassandra N.
    Healy, Eamonn F.
    King, Peter
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 245
  • [28] Pharmacodynamic biomarker evaluation in phase I clinical trials of selective PI3K and PI3K/mTOR inhibitors
    Nakanishi, Yoshito
    Spoerke, Jill M.
    Derynck, Mika
    Lauchle, Jennifer O.
    Koeppen, Hartmut
    Fredrickson, Jill
    Ware, Joseph
    Hampton, Garret
    Yan, Yibing
    Lackner, Mark R.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2015, 14 (07)
  • [29] Isoform-Selective PI3K Inhibitors for Various Diseases
    Bheemanaboina, Rammohan R. Y.
    [J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2020, 20 (12) : 1074 - 1092
  • [30] Taking PI3Kδ and PI3Kγ One Step Ahead: Dual Active PI3Kδ/γ Inhibitors for the Treatment of Immune-Mediated Inflammatory Diseases
    Rommel, Christian
    [J]. PHOSPHOINOSITIDE 3-KINASE IN HEALTH AND DISEASE, VOL 1, 2010, 346 : 279 - 299